Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.

In a subgroup of patients with metastatic clear-cell renal cell carcinoma (m-ccRCC), immune checkpoint (ICP) inhibitors can induce considerable and longlasting responses. However, predictive biomarkers are lacking. We report a case of a long-lasting deep partial response with nivolumab treatment in an m-ccRCC patient with a germ line pathogenic breast cancer-1 mutation. This observation is consistent with 2 patient series presented recently at the annual genitourinary cancer symposium of the American Society of Clinical Oncology (ASCO-GU 2019), showing favorable outcomes with ICP inhibitors in m-ccRCC patients with somatic or germ line mutations in DNA damage repair genes. (C) 2019 Elsevier Inc. All rights reserved.